The encouraging findings about GLP-1 RAs, although not obtained in kidney disease-focused primary-outcome trials, might add an additional therapeutic option and potentially provide an upstream treatment for patients with kidney disease. The gene discussed is GLP1R; the disease is kidney disorder.